nimacimab glp-1 news Skye Bioscience, Inc. (SKYE) Securities Class Action Lawsuit Update [December 10, 2025] A wave of new #GLP1

Himss membership bundles 24/7 provider access, personalized nutrition guidance, ongoing clinical check-ins, app-based tracking, and a peer support community

Skye is conducting a Phase 2 clinical trial ( ClinicalTrials.gov: NCT06577090 ) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1

This is what it must feel like for someone who doesn't have to live with obesity, who has normal appetite regulation and is not thinking about food all the time." Dr

The obstruction occurred after a reasonable exposure window , often within months of dose escalation or prolonged use

It is taken once a week at the same time and day

, Habib, A